ATE183516T1 - Waisen-rezeptor - Google Patents

Waisen-rezeptor

Info

Publication number
ATE183516T1
ATE183516T1 AT96931047T AT96931047T ATE183516T1 AT E183516 T1 ATE183516 T1 AT E183516T1 AT 96931047 T AT96931047 T AT 96931047T AT 96931047 T AT96931047 T AT 96931047T AT E183516 T1 ATE183516 T1 AT E183516T1
Authority
AT
Austria
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
AT96931047T
Other languages
English (en)
Inventor
George G J Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE183516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of ATE183516T1 publication Critical patent/ATE183516T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT96931047T 1995-09-08 1996-09-09 Waisen-rezeptor ATE183516T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor

Publications (1)

Publication Number Publication Date
ATE183516T1 true ATE183516T1 (de) 1999-09-15

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931047T ATE183516T1 (de) 1995-09-08 1996-09-09 Waisen-rezeptor

Country Status (12)

Country Link
US (2) US5958710A (de)
EP (2) EP0792292B2 (de)
JP (4) JP3131649B2 (de)
KR (1) KR100263137B1 (de)
AT (1) ATE183516T1 (de)
AU (1) AU715528B2 (de)
CA (1) CA2201098C (de)
DE (2) DE792292T1 (de)
DK (1) DK0792292T4 (de)
ES (1) ES2135249T5 (de)
GR (2) GR980300029T1 (de)
WO (1) WO1997009348A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (de) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, ein Steroid Hormon Rezeptor Homolog
KR20010013631A (ko) * 1997-06-10 2001-02-26 오테스코그 페르 에스트로겐 수용체 리간드
US7157568B1 (en) 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ATE335820T1 (de) * 1997-09-08 2006-09-15 Merck & Co Inc Östrogenrezeptor
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (de) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogenrezeptoren und Knochenkrankheit
DK1165184T3 (da) * 1999-04-09 2004-04-13 Karobio Ab Estrogenreceptor-beta antagonisme og knoglesygdomme
WO2002064783A2 (en) * 2001-02-09 2002-08-22 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
ES2427626T3 (es) 2003-02-21 2013-10-31 Styron Europe Gmbh Procedimiento para homo- o copolimerización de olefinas conjugadas
CN100374444C (zh) 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
MXPA06001094A (es) 2003-07-28 2006-04-11 Smithkline Beecham Corp Compuestos quimicos.
US20050186645A1 (en) * 2003-12-18 2005-08-25 Yehudit Amor Method for analyzing a glycomolecule
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
US5597693A (en) * 1989-03-17 1997-01-28 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
DK0792292T3 (da) 2000-02-07
EP0792292A2 (de) 1997-09-03
US20030113803A1 (en) 2003-06-19
ES2135249T5 (es) 2009-09-10
JP2002010788A (ja) 2002-01-15
DK0792292T4 (da) 2009-07-20
US7132261B2 (en) 2006-11-07
EP0935000A3 (de) 1999-09-08
WO1997009348A3 (en) 1997-04-24
WO1997009348A2 (en) 1997-03-13
AU6988096A (en) 1997-03-27
EP0935000A2 (de) 1999-08-11
ES2135249T3 (es) 1999-10-16
EP0792292B1 (de) 1999-08-18
JP2005204667A (ja) 2005-08-04
JP3131649B2 (ja) 2001-02-05
GR980300029T1 (en) 1998-04-30
CA2201098C (en) 2001-03-27
US5958710A (en) 1999-09-28
JP2005204666A (ja) 2005-08-04
DE69603827T2 (de) 2000-02-24
AU715528B2 (en) 2000-02-03
EP0792292B2 (de) 2009-04-15
JPH11502417A (ja) 1999-03-02
GR3031618T3 (en) 2000-01-31
DE69603827T3 (de) 2009-11-05
CA2201098A1 (en) 1997-03-13
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
KR100263137B1 (ko) 2000-08-01

Similar Documents

Publication Publication Date Title
DK0792292T3 (da) Orphan-receptor
EP1028758A4 (de) Verfahren zur behandlung von prostattumoren mit radioaktiven zusammensetzungen
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
AU6045398A (en) Androgen synthesis inhibitors
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
PL328858A1 (en) Immunogenous peptides
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
WO1996035784A3 (de) Chromatin-regulatorgene
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
LEVI-MONTALCINI et al. Hormonal control of the NGF content in the submaxillary glands of mice
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
DK0988040T3 (da) Anvendelse af glucosamin og glucasamin-derivater til hurtig lindring af klöe eller lokaliseret smerte
BR9808784A (pt) Método para o tratamento de doença mental em mamìferos e uma composição para o mesmo
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
NO972313D0 (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0792292

Country of ref document: EP